首页> 美国卫生研究院文献>British Journal of Cancer >A phase I study of E7080 a multitargeted tyrosine kinase inhibitor in patients with advanced solid tumours

【2h】

A phase I study of E7080 a multitargeted tyrosine kinase inhibitor in patients with advanced solid tumours

机译：多目标酪氨酸激酶抑制剂E7080在患有晚期实体瘤的患者中进行的I期研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: The objectives of this phase I study were to assess the safety and tolerability of E7080 in patients with advanced, refractory solid tumours; to determine the maximum tolerated dose (MTD) and pharmacokinetics profile of E7080; and to explore preliminary evidence of its anti-tumour efficacy.

机译：背景：I期研究的目的是评估E7080在晚期难治性实体瘤患者中的安全性和耐受性。确定E7080的最大耐受剂量（MTD）和药代动力学曲线；并探索其抗肿瘤功效的初步证据。

著录项

期刊名称 British Journal of Cancer
作者
D S Boss; H Glen; J H Beijnen; M Keesen; R Morrison; B Tait; W Copalu; A Mazur; J Wanders; J P OBrien; J H M Schellens; T R J Evans;
展开▼
作者单位

展开▼
年(卷),期 2012(106),10
年度 2012
页码 1598–1604
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
dose escalation E7080 pharmacokinetics phase I receptor tyrosine kinase inhibitor solid tumours;

机译：剂量递增;E7080;药代动力学;I期;受体酪氨酸激酶抑制剂;实体瘤;

相似文献

外文文献
中文文献
专利

1. A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours [J] . D S Boss, H Glen, J H Beijnen, British Journal of Cancer . 2012,第10期

机译：E7080，一种多靶点酪氨酸激酶抑制剂，在晚期实体瘤患者中进行的I期研究
2. A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies [J] . Das Millie, Padda Sukhmani K., Frymoyer Adam, Cancer chemotherapy and pharmacology. . 2018,第3期

机译：具有晚期固体恶性肿瘤患者的间歇和连续给药调度，对多元小分子酪氨酸激酶抑制剂XL647的一种安全性，耐受性和药代动力学分析
3. A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors [J] . Molife L. Rhoda, Dean Emma Jane, Blanco-Codesido Montserrat, Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第24期

机译：晚期实体瘤患者多靶点受体酪氨酸激酶抑制剂Golvatinib的I期剂量递增研究
4. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours [O] . I R H M Konings, M J A de Jonge, H Burger, 2010

机译：广谱酪氨酸激酶抑制剂JNJ-26483327在晚期实体瘤患者中的I期和药理研究
7. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. [O] . Molife, L Rhoda, Dean, Emma Jane, Blanco-Codesido, Montserrat, 2014

机译：对于晚期实体瘤患者，多靶点受体酪氨酸激酶抑制剂golvatinib的I期剂量递增研究。

A phase I study of E7080 a multitargeted tyrosine kinase inhibitor in patients with advanced solid tumours

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅